Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer progression or death risk by 26% compared to standard chemotherapy. The ...

Please provide your email address to receive an email when new articles are posted on . Most patients in a phase 2 trial responded to a non-cryopreserved tandem CAR-T. Most trial participants received ...

The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell ...

Odronextamab demonstrated a 48.3% objective response rate and 31.7% complete response rate in R/R DLBCL patients post-CAR-T therapy. The median duration of response was 14.8 months, with ...

Major proposed mechanisms of immune evasion by lymphoma cells and the related molecules involved in each mechanism: “Hide” (MHC-I, MHC-II, CD58, CD54, CD80, CD86), “Defend” (CD95/FAS, BCL-2), ...

Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) reduces the risk for disease progression, relapse, or death by 37% vs standard therapy in patients ≥ 70 ...

Almost 40% of patients with relapsed/refractory lymphomas achieved complete responses (CRs) with a five-drug regimen that targeted different cancer-survival pathways, a preliminary clinical trial ...

At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients ...

COPENHAGEN, Dec 13 (Reuters) - Danish biotech firm Genmab said on Thursday it started a Phase II trial with its ofatumumab (HuMax-CD20) drug for relapsed diffuse large b-cell lymphoma (DLBCL). The 75 ...